Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Topline data expected to be available late 3Q2027 Topline data expected to be available late 3Q2027
Topline data expected to be available late 3Q2027 Topline data expected to be available late 3Q2027
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.